Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Alexander L. Vahrmeijer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9370-0011; OpenAlex author ID A5028075025. Sources: ClinicalTrials.gov.

Their work

Papers
47 (first author 1, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
103
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers, 1 trial · 2017: 4 papers · 2018: 9 papers · 2019: 6 papers · 2020: 3 papers · 2021: 7 papers · 2022: 5 papers · 2023: 6 papers · 2024: none · 2025: 4 papers

Papers 47

  1. Both skeletal muscle index and muscle attenuation are associated with frailty in preoperative older patients with pancreatic cancer. Co-author DOI 10.1016/j.clnu.2025.11.004↗
  2. Revolutionizing Solid Tumor Surgery with Fibroblast Activation Protein (FAP)-Targeted Imaging Probes for a Fluorescence-Guided Surgery of Pancreatic Cancer. Co-author DOI 10.1021/acs.bioconjchem.5c00218↗
  3. Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-00517-1↗
  4. Computer-Aided Decision Support and 3D Models in Pancreatic Cancer Surgery: A Pilot Study. Co-author DOI 10.3390/jcm14051567↗
  5. Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecu… Co-author DOI 10.1007/s40291-022-00635-w↗
  6. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101909↗
  7. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study. Co-author DOI 10.1245/s10434-023-13112-3↗
  8. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation S… Co-author DOI 10.2967/jnumed.121.263773↗
  9. Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using a Fluorescently Labelled Anti-CEA Nanobody Probe: A Preclinical Study. Co-author DOI 10.3390/biom13040618↗
  10. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  11. The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer. Last author DOI 10.1097/cad.0000000000001283↗
  12. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. Co-author DOI 10.1136/jitc-2022-004638↗
  13. A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.3390/cancers14163862↗
  14. Prostate-Specific Membrane Antigen Targeted Pet/CT Imaging in Patients with Colon, Gastric and Pancreatic Cancer. Co-author DOI 10.3390/cancers14246209↗
  15. Single fiber reflectance spectroscopy for pancreatic cancer detection during endoscopic ultrasound guided fine needle biopsy: a prospective cohort study. Co-author DOI 10.7150/ijms.65364↗
  16. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. First author DOI 10.1007/s13402-021-00587-z↗
  17. Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. Co-author DOI 10.1016/j.thromres.2021.08.002↗
  18. Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer: Pathological Assessment and Recurrence Patterns. Co-author DOI 10.1097/mpa.0000000000001897↗
  19. An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13225777↗
  20. The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13225789↗
  21. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.3390/cancers13236088↗
  22. Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13246164↗
  23. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Co-author DOI 10.1038/s41598-020-73242-6↗
  24. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Co-author DOI 10.1080/1354750x.2020.1725786↗
  25. Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center St… Co-author DOI 10.3390/cancers12102970↗
  26. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Co-author DOI 10.1002/bjs.11115↗
  27. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). Co-author DOI 10.1016/j.eclinm.2019.10.013↗
  28. Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. Co-author DOI 10.1016/j.ejso.2019.06.004↗
  29. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2018.11.008↗
  30. A Prospective Clinical Trial to Determine the Effect of Intraoperative Ultrasound on Surgical Strategy and Resection Outcome in Patients with Pancreatic Cancer. Co-author DOI 10.1016/j.ultrasmedbio.2019.04.020↗
  31. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Co-author DOI 10.1126/sciadv.aax2770↗
  32. Fluorescent-guided surgery for sentinel lymph node detection in gastric cancer and carcinoembryonic antigen targeted fluorescent-guided surgery in colorectal a… Last author DOI 10.1002/jso.25139↗
  33. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. Co-author DOI 10.1007/s11605-017-3541-8↗
  34. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.004↗
  35. Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001075↗
  36. Development and Preclinical Validation of a Cysteine Knottin Peptide Targeting Integrin αvβ6 for Near-infrared Fluorescent-guided Surgery in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2491↗
  37. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Co-author DOI 10.1245/s10434-018-6453-2↗
  38. Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infr… Last author DOI 10.1245/s10434-018-6655-7↗
  39. ASO Author Reflections: Fluorescent-Guided Surgery to Augment Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-018-6904-9↗
  40. Correction to: ASO Author Reflections: Fluorescent-Guided Surgery to Augment Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-018-7065-6↗
  41. Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. Co-author DOI 10.1136/jclinpath-2016-203928↗
  42. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells. Co-author DOI 10.1177/1177271917715443↗
  43. Validation of full-field optical coherence tomography in distinguishing malignant and benign tissue in resected pancreatic cancer specimens. Co-author DOI 10.1371/journal.pone.0175862↗
  44. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.18232↗
  45. Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Co-author DOI 10.1007/s11307-016-0959-4↗
  46. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care. Co-author DOI 10.1007/s11605-015-2951-8↗
  47. Current and future intraoperative imaging strategies to increase radical resection rates in pancreatic cancer surgery. Co-author DOI 10.1155/2014/890230↗

Trials 1

  1. Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas Principal investigator NCT02973672↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. J. Sven D. Mieog · 29 shared papers, 2014–2025 · strength 3.66
  2. Bert A. Bonsing · 30 shared papers, 2014–2025 · strength 3.23
  3. Rutger‐Jan Swijnenburg · 18 shared papers, 2016–2023 · strength 1.68
  4. Ruben D. Houvast · 6 shared papers, 2021–2025 · strength 1.03
  5. Peter J.K. Kuppen · 9 shared papers, 2016–2025 · strength 0.99
  6. Noel F.C.C. de Miranda · 5 shared papers, 2021–2022 · strength 0.86
  7. Jesse V. Groen · 7 shared papers, 2019–2023 · strength 0.84
  8. Willemieke S. F. J. Tummers · 9 shared papers, 2016–2019 · strength 0.77
  9. Labrinus van Manen · 6 shared papers, 2017–2023 · strength 0.77
  10. Floris A. Vuijk · 6 shared papers, 2018–2023 · strength 0.75
  11. Cornelis F.M. Sier · 8 shared papers, 2016–2023 · strength 0.74
  12. Lysanne D. A. N. de Muynck · 4 shared papers, 2020–2025 · strength 0.72
  13. Thomas P. Brouwer · 4 shared papers, 2021–2022 · strength 0.67
  14. Marc G. Besselink · 4 shared papers, 2020–2025 · strength 0.53
  15. Hans Morreau · 6 shared papers, 2016–2022 · strength 0.52
  16. Babs G. Sibinga Mulder · 5 shared papers, 2017–2023 · strength 0.49
  17. Bas Groot Koerkamp · 4 shared papers, 2019–2025 · strength 0.47
  18. Susanna W.L. de Geus · 6 shared papers, 2016–2019 · strength 0.42
  19. George A. Poultsides · 4 shared papers, 2018–2019 · strength 0.38
  20. Eben Lloyd Rosenthal · 4 shared papers, 2018–2019 · strength 0.38
  21. Nynke Michiels · 2 shared papers, 2023–2025 · strength 0.38
  22. Lukas J.A.C. Hawinkels · 2 shared papers, 2022–2025 · strength 0.36
  23. Casper H.J. van Eijck · 4 shared papers, 2017–2021 · strength 0.35
  24. Sanjiv Sam Gambhir · 4 shared papers, 2018–2019 · strength 0.33
  25. Ricki T. Krog · 2 shared papers, 2021–2022 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.